• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

出版信息

Liver Cancer. 2022 Jun 13;11(4):283-289. doi: 10.1159/000525467. eCollection 2022 Jul.

DOI:10.1159/000525467
PMID:35978599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9294945/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/cc0fadba1a95/lic-0011-0283-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/8fd35c5e9643/lic-0011-0283-gu01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/d17e6eb97e33/lic-0011-0283-gu02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/6eccc953801b/lic-0011-0283-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/14437db6525c/lic-0011-0283-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/cc0fadba1a95/lic-0011-0283-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/8fd35c5e9643/lic-0011-0283-gu01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/d17e6eb97e33/lic-0011-0283-gu02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/6eccc953801b/lic-0011-0283-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/14437db6525c/lic-0011-0283-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18ff/9294945/cc0fadba1a95/lic-0011-0283-g03.jpg

相似文献

1
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?不可切除肝细胞癌全身治疗方案的选择：病因学有影响吗？
Liver Cancer. 2022 Jun 13;11(4):283-289. doi: 10.1159/000525467. eCollection 2022 Jul.
2
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
3
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma. Tremelimumab：在晚期或不可切除的肝细胞癌中的研究进展。
Target Oncol. 2024 Jan;19(1):115-123. doi: 10.1007/s11523-023-01026-9. Epub 2024 Jan 18.
4
External beam radiotherapy for unresectable hepatocellular carcinoma.不可切除肝细胞癌的外照射放疗
Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.
5
Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.贝伐珠单抗和阿替利珠单抗治疗不可切除肝细胞癌：台湾台南医学肿瘤群组 H01 试验的真实世界数据。
In Vivo. 2023 Jan-Feb;37(1):454-460. doi: 10.21873/invivo.13099.
6
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.不可切除肝细胞癌的治疗选择，重点是使用钇-90树脂微球的选择性内放射治疗（SIRT）
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.
7
The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.PD-1 抑制剂联合 TACE 用于不可切除肝细胞癌一线治疗的疗效和安全性。
Med Oncol. 2024 Mar 25;41(5):91. doi: 10.1007/s12032-024-02309-5.
8
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.信迪利单抗联合贝伐珠单抗生物类似药（IBI305）对比索拉非尼治疗不可切除肝细胞癌（ORIENT-32）：一项随机、开放标签的2/3期研究
Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.
9
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort.免疫治疗时代的不可切除肝细胞癌：来自法国前瞻性 CHIEF 队列的真实世界数据。
Eur J Gastroenterol Hepatol. 2023 Oct 1;35(10):1168-1177. doi: 10.1097/MEG.0000000000002546. Epub 2023 Aug 11.
10
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.

引用本文的文献

1
Precision models in hepatocellular carcinoma.肝细胞癌中的精准模型
Nat Rev Gastroenterol Hepatol. 2025 Mar;22(3):191-205. doi: 10.1038/s41575-024-01024-w. Epub 2024 Dec 11.
2
Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.外周血T细胞亚群作为阿替唑单抗联合贝伐单抗治疗肝细胞癌期间潜在替代生物标志物的研究
Cancers (Basel). 2024 Mar 28;16(7):1328. doi: 10.3390/cancers16071328.
3
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.

本文引用的文献

1
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass.抗PD-1/PD-L1抗体联合抗VEGF抗体的联合免疫疗法可能促进肝细胞癌（包括非炎症亚类）中的细胞毒性T淋巴细胞浸润。
Liver Cancer. 2022 May 10;11(3):185-191. doi: 10.1159/000524977. eCollection 2022 Jun.
2
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
3
接受联合免疫治疗联合局部区域治疗后达到临床完全缓解的肝细胞癌患者的停药标准
Liver Cancer. 2023 Jul 28;12(4):289-296. doi: 10.1159/000532023. eCollection 2023 Sep.
4
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.肝细胞癌系统性治疗的新时代：从一线治疗到最佳序贯治疗。
Curr Oncol. 2023 Sep 26;30(10):8774-8792. doi: 10.3390/curroncol30100633.
5
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌患者早期进展性疾病的预测。
Cancer Med. 2023 Sep;12(17):17559-17568. doi: 10.1002/cam4.6369. Epub 2023 Aug 3.
6
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma.肝细胞癌切除或消融术后辅助使用阿替利珠单抗-贝伐珠单抗
Liver Cancer. 2023 May 24;12(3):189-197. doi: 10.1159/000531225. eCollection 2023 Aug.
7
Evolving therapeutic landscape of advanced hepatocellular carcinoma.晚期肝细胞癌不断演变的治疗格局。
Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11.
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
日本肝细胞癌的管理：2021年更新版日本肝脏学会共识声明与建议
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
4
Cabozantinib: An evolving therapy for hepatocellular carcinoma.卡博替尼：用于肝细胞癌的不断发展的治疗方法。
Cancer Treat Rev. 2021 Jul;98:102221. doi: 10.1016/j.ctrv.2021.102221. Epub 2021 May 12.
5
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
6
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.抗PD-1/PD-L1单药疗法对肝细胞癌的疗效有限。
Liver Cancer. 2020 Dec;9(6):629-639. doi: 10.1159/000512170. Epub 2020 Oct 26.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
9
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab（REACH-2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
10
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.日本全国范围内非乙型、非丙型肝细胞癌的调查：2011-2015 年更新。
J Gastroenterol. 2019 Apr;54(4):367-376. doi: 10.1007/s00535-018-1532-5. Epub 2018 Nov 29.